Who was studied, and how
Three numbers in the abstract
Where each one falls
Only readable comparisons vote
Where it lands on the map
What it changes
Among 9 other studies
37,934people with cardiovascular disease, in this paper
The trial randomly assignedassigned by chance
Alirocumab
Evolocumab
No clear effect on major heart events−16%
randomisedThe trial randomly assignedassigned by chance
PCSK9 inhibitors
control (placebo or standard care)
Lowered LDL cholesterol−52.7
Lowered major heart events−21%
randomisedthe abstract, start to end
… not statistically significant (OR: 0.84; 95% CI: 0.68-1.03).
… reduced LDL-C (mean difference [MD]: - 52.7 mg/dL; 95% CI: - 61.2 to - 44.1) and lowered the risk of MACE (odds ratio [OR]: 0.79; 95% CI: 0.68-0.93).
← favours treatmentfavours comparator →
could be chanceMACEAlirocumab vs Evolocumab
OR 0.840.68–1.03
LDL-CPCSK9 inhibitors vs control (placebo or standard care)
−52.7−61.2 to −44.1
MACEPCSK9 inhibitors vs control (placebo or standard care)
OR 0.790.68–0.93
PCSK9 inhibitorsLipidsCardiovascular events
PCSK9 inhibitors × cardiovascular eventshelps?settled
unlikelylikely
1.00not counted
PCSK9 inhibitors × lipidshelps?settled
unlikelylikely
0.93not counted
← favours treatmentfavours comparator →
1 / 7